Therapy of immune neuropathies with intravenous immunoglobulins.
Autoimmune-mediated disorders belong to the main causes of neuropathies worldwide. During recent years much progress has been achieved in the understanding of the underlying pathomechanisms, associated with implications for therapeutic approaches. Here we will briefly review the pathogenesis and discuss treatment options of the Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy, multifocal motor neuropathy, and neuropathies associated with paraproteinemias. In most of these disease entities intravenous immunoglobulins play a major role as effective and safe treatment options.
Gold
Ralf
R
Institute for MS research, Waldweg 33, 37073, Göttingen, Germany. r.gold@med.uni-goettingen.de
Kieseier
Bernd C
BC
D020275:Guillain-Barre Syndrome / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D009422:Nervous System Diseases / Q000188:drug therapy / Q000276:immunology; D010265:Paraproteinemias / Q000150:complications; D020277:Polyradiculoneuropathy, Chronic Inflammatory Demyelinating / Q000188:drug therapy* / Q000276:immunology
D016756:Immunoglobulins, Intravenous